Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Acronyms TUBERCULOSIS-017
- Sponsors GlaxoSmithKline
- 30 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.